Close Menu

NEW YORK (GenomeWeb) – Grifols said on Thursday that it will acquire a 26.2 percent stake in Shanghai RAAS as part of a strategic alliance agreement to manufacture, market, and develop plasma products and transfusion diagnostic solutions in the Chinese market.

Under the agreement, Grifols will acquire its stake in Shanghai RAAS in exchange for 45 percent of the economic rights and 40 percent of the voting rights of Grifols Diagnostic Solutions, its US subsidiary. Grifols Diagnostic Solutions' valuation is $4.28 billion, and the price per share of Shanghai RAAS is RMB 7.50.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

James Wyngaarden, the former director of the US National Institutes of Health, has died at 94, according to Duke University School of Medicine.

The Associated Press reports that a state board in Texas has asked ANDE, a maker of rapid DNA machines, to halt its work there.

Researchers find that a 30-year-old skull comes from a narwhal-beluga hybrid, according to Science News.

In Nature this week: study of value diversity in GWAS, Epstein-Barr virus subtypes linked to nasopharyngeal carcinoma risk, and more.